|Day Low/High||4.10 / 4.42|
|52 Wk Low/High||8.42 / 23.98|
The most recent short interest data was recently released for the 05/15/2017 settlement date, and OncoMed Pharmaceuticals Inc. is one of the most shorted stocks of the Russell 3000, based on 5.29 "days to cover" versus the median component at 4.71.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of OncoMed Pharmaceuticals Inc.
Horizon Pharma, OncoMed Pharmaceuticals and Inovio Pharmaceuticals were among the biotech stock movers in early trading on Monday.
Phase 1a Study Will Assess Novel Checkpoint Inhibitor as a Single Agent in Solid Tumors
Extends Projected Cash Runway through Q3 2019 to Focus on Clinical-Stage Programs and Immuno-Oncology Discovery and Development
Stocks close in positive territory Monday ahead of a big week for U.S. corporate earnings.
Stocks remained in positive territory breaking a three-day losing streak ahead of U.S. corporate earnings this week, despite mounting tension between North Korea and the U.S.
Stocks rise on Monday ahead of a big week for U.S. corporate earnings, including reports Monday from Netlfix and United Airlines.
Stocks rise on Monday ahead of a big week for U.S. corporate earnings and as the U.S. issues a warning to North Korea.
OncoMed Pharmaceuticals, Incyte and Omeros were among the biotech stock movers in premarket trading on Monday.
OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
OncoMed Retains Worldwide Rights to Both Wnt Pathway Programs
OncoMed Management to Host Conference Call/Webcast at 8:30 a.m. ET/5:30 a.m. PT to Review Top-line Results
Translational Research for Tarextumab, Rosmantuzumab and GITRL-Fc Trimer to Inform Clinical Programs
Anti-TIGIT Demonstrates Potent Anti-Tumor Activity in Preclinical Models
The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 1,022,767 share increase in total short interest for OncoMed Pharmaceuticals Inc. , to 2,831,493, an increase of 56.55% since 02/28/2017.
Additional Presentations will Highlight New Biomarker and Xenograft Data for Clinical Programs
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in OncoMed Pharmaceuticals Inc. , where a total of 1,100 contracts have traded so far, representing approximately 110,000 underlying shares.
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.